

Title (en)  
IMMUNOTOXINS DIRECTED AGAINST CD33 RELATED SURFACE ANTIGENS.

Title (de)  
GEGEN CD33 VERWANDTE OBERFLÄCHEN-ANTIGENE GERICHTETE IMMUNTOXINE.

Title (fr)  
IMMUNOTOXINES DIRIGÉES CONTRE DES ANTIGÈNES DE SURFACE RELATIFS A CD33.

Publication  
**EP 0634938 A4 19980603 (EN)**

Application  
**EP 93912143 A 19930408**

Priority  
• US 9303284 W 19930408  
• US 86669392 A 19920410

Abstract (en)  
[origin: WO9320848A1] The present invention provides novel immunotoxins and methods of treating neoplastic diseases. These immunotoxins are comprised of a conjugation of an antigen binding region exhibiting binding specificity for the CD33 protein and a cell growth modulator. The immunotoxins of the present invention specifically and selectively kill tumor cells that are characterized by the expression of CD33 antigen. Thus, the novel immunotoxins would be useful in treating human leukemias, both acute and chronic, and other myelodysplastic syndromes.

IPC 1-7  
**A61K 39/395**; **C07K 15/28**; **C12P 21/08**

IPC 8 full level  
**C12N 15/09** (2006.01); **A61K 39/395** (2006.01); **A61K 47/48** (2006.01); **A61P 7/06** (2006.01); **A61P 35/02** (2006.01); **C07K 14/415** (2006.01); **C07K 16/30** (2006.01); **C07K 19/00** (2006.01); **C12P 21/08** (2006.01); **C12R 1/91** (2006.01)

CPC (source: EP KR)  
**A61K 38/01** (2013.01 - KR); **A61K 39/395** (2013.01 - KR); **A61K 47/6425** (2017.07 - EP); **A61P 7/06** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 35/02** (2017.12 - EP); **C07K 16/2803** (2013.01 - EP)

Citation (search report)  
• [Y] EP 0350230 A2 19900110 - RES DEV FOUNDATION [US]  
• [Y] WO 9109058 A1 19910627 - SLOAN KETTERING INST CANCER [US]  
• [X] SCHEINBERG ET AL.: "Humanized and Mouse Anti-CD33-Gelolin Immunotoxins for Myeloid Leukemias", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 33, March 1992 (1992-03-01), pages 346, XP002061680  
• [DY] MAN SUNG CO: "CHIMERIC AND HUMANIZED ANTIBODIES WITH SPECIFICITY FOR THE CD33 ANTIGEN1", JOURNAL OF IMMUNOLOGY, vol. 148, no. 4, 15 February 1992 (1992-02-15), pages 1149 - 1154, XP000368716  
• [Y] SCHEINBERG D A ET AL: "A PHASE I TRIAL OF MONOCLONAL ANTIBODY M195 IN ACUTE MYELOGENOUS LEUKEMIA: SPECIFIC BONE MARROW TERGETING AND INTERNALIZATION OF RADIONUCLIDE", JOURNAL OF CLINICAL ONCOLOGY, vol. 9, no. 3, 1 March 1991 (1991-03-01), pages 478 - 490, XP000564602  
• See references of WO 9320848A1

Designated contracting state (EPC)  
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)  
**WO 9320848 A1 19931028**; AU 4280193 A 19931118; AU 675226 B2 19970130; CA 2133838 A1 19931028; CA 2133838 C 20030729; CN 1056084 C 20000906; CN 1078401 A 19931117; EP 0634938 A1 19950125; EP 0634938 A4 19980603; EP 1656950 A1 20060517; FI 944730 A0 19941007; FI 944730 A 19941007; IL 105344 A0 19930818; IL 105344 A 20000629; JP 3949158 B2 20070725; JP H08501059 A 19960206; KR 100291377 B1 20010917; KR 950700760 A 19950220; NO 314686 B1 20030505; NO 943776 D0 19941007; NO 943776 L 19941125; NZ 252799 A 19961028; RU 2127122 C1 19990310; ZA 932523 B 19941008

DOCDB simple family (application)  
**US 9303284 W 19930408**; AU 4280193 A 19930408; CA 2133838 A 19930408; CN 93104200 A 19930409; EP 04017939 A 19930408; EP 93912143 A 19930408; FI 944730 A 19941007; IL 10534493 A 19930408; JP 51845793 A 19930408; KR 19940703547 A 19941007; NO 943776 A 19941007; NZ 25279993 A 19930408; RU 94045984 A 19930408; ZA 932523 A 19930101